Functional screening of amplification outlier oncogenes in organoid models of early tumorigenesis

Other authors

Institut Català de la Salut

[Salahudeen AA] Stanford University School of Medicine, Department of Medicine, Divisions of Hematology, Stanford, CA, USA. University of Illinois at Chicago College of Medicine, Department of Medicine, Division of Hematology and Oncology, Chicago, IL, USA. Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago College of Medicine, Chicago, IL, USA. University of Illinois Cancer Center, Chicago, IL, USA. [Seoane JA] Stanford University School of Medicine, Department of Medicine, Divisions of Oncology, Stanford, CA, USA. Cancer Computational Biology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Yuki K, Mah AT, Smith AR, Kolahi K] Stanford University School of Medicine, Department of Medicine, Divisions of Hematology, Stanford, CA, USA

Vall d'Hebron Barcelona Hospital Campus

Publication date

2023-11-17T08:40:05Z

2023-11-17T08:40:05Z

2023-11-28



Abstract

Genomics; Organoid; Squamous cancer


Genómica funcional; Organoide; Cáncer escamoso


Genòmica funcional; Organoide; Càncer escamós


Somatic copy number gains are pervasive across cancer types, yet their roles in oncogenesis are insufficiently evaluated. This inadequacy is partly due to copy gains spanning large chromosomal regions, obscuring causal loci. Here, we employed organoid modeling to evaluate candidate oncogenic loci identified via integrative computational analysis of extreme copy gains overlapping with extreme expression dysregulation in The Cancer Genome Atlas. Subsets of “outlier” candidates were contextually screened as tissue-specific cDNA lentiviral libraries within cognate esophagus, oral cavity, colon, stomach, pancreas, and lung organoids bearing initial oncogenic mutations. Iterative analysis nominated the kinase DYRK2 at 12q15 as an amplified head and neck squamous carcinoma oncogene in p53−/− oral mucosal organoids. Similarly, FGF3, amplified at 11q13 in 41% of esophageal squamous carcinomas, promoted p53−/− esophageal organoid growth reversible by small molecule and soluble receptor antagonism of FGFRs. Our studies establish organoid-based contextual screening of candidate genomic drivers, enabling functional evaluation during early tumorigenesis.


This work was supported by the NCI Cancer Target Discovery and Development (CTD∧2) Network (U01CA217851, C.J.K and C.C.; U01CA176058, W.C.H.). Support was also provided by NIH K08DE027730 and D.R. discretionary funds to A.A.S., AEI RYC2019- 026576-I, “LaCaixa” Foundation LCF/PR/PR17/51120011 to J.A.S., and NIH U54CA224081, NIH U01CA199241, Emerson Collective, Ludwig Cancer Research, and Stand Up To Cancer to C.J.K. This manuscript is dedicated to the memories of Dr. Daniela Gerhard and Dr. Kenneth Scott.

Document Type

Article


Published version

Language

English

Publisher

Cell Press

Related items

Cell Reports;42(11)

https://doi.org/10.1016/j.celrep.2023.113355

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)